Navigation Links
Lumiracoxib Study Showed Significantly Less Impact on Blood,Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension

artis Pharma AG. "The new research underlines how important it is for osteoarthritis patients to have a treatment option such as lumiracoxib."

The study presented at EULAR was a four-week, multicenter, randomized, double-blind, double-dummy, parallel group trial of 787 hypertensive osteoarthritis patients age 50 or older with ambulatory blood pressure of 140/90 mmHg or below, and who were being treated with an antihypertensive medicine. A total of 741 patients completed the study, which compared lumiracoxib 100 mg once-daily with ibuprofen 600 mg taken three times daily.

At the end of the study, patients on lumiracoxib showed a decrease in mean ambulatory systolic blood pressure of 2.7 mmHg compared to a 2.2 mmHg increase in patients taking ibuprofen, giving an estimated difference of 5.0 mmHg between the groups (p<0.001). Mean ambulatory diastolic blood pressure decreased by 1.5 mmHg in lumiracoxib patients compared to a 0.5 mmHg increase in those on ibuprofen, an estimated difference of 2.0 mmHg (p<0.001).

Systolic pressure represents the pressure within blood vessels when the heart contracts, while diastolic pressure is measured when the heart is at rest between beats. Both are monitored while the patient is active (or 'ambulatory'), considered to be the most rigorous way of studying blood pressure. They are measured in millimeters of mercury or mmHg.

Results further showed lumiracoxib and ibuprofen had similar efficacy as well as a comparable incidence of adverse events. These were mostly mild and did not indicate treatment-limiting toxicity. The most common adverse event in both treatment groups was upper abdominal pain, which occurred in less than 2% of patients.

Lumiracoxib has a different chemical structure from other COX-2 inhibitors. It is the only one that does not contain a sulphur molecule, which has been associated with sulphur-related skin reactions in some patients. Lumiracoxib also has a plasma half-life of approxi
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:1/14/2014)... Calif. , Jan. 14, 2014 The Brandeis Medical Center, ... Angeles a premier and affordable laser tattoo removal experience ... Dr. Brandeis, focus is in providing high quality cosmetic services with ... patients. " Southern California has seen ...
(Date:1/14/2014)... Emergency Critical Care, a LifeCentre partner practice, located at 165 Fort ... first in Loudoun County to receive a ... M. Barnes , Medical Director, is a well-seasoned veterinarian of more ... , are avid scuba divers. "As altitude skiers and hikers, we ...
(Date:1/14/2014)... Oligomerix, Inc. , a privately held company pioneering the ... and related neurodegenerative disorders, announced today the relocation of ... as of January 15, 2014 and expanded lease ... College. Oligomerix, which is focused on the ...
Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... WOONSOCKET, R.I., Feb. 14, 2012  CVS Caremark (NYSE: ... impact study of CVS Caremark,s contribution to the ... company,s national headquarters is located.  According to the ... for CVS Caremark, the company,s Rhode Island operations ...
... Feb. 14, 2012 Watson Pharmaceuticals, Inc. (NYSE: ... $1.5 billion for the fourth quarter ended December 31, 2011, ... a non-GAAP basis, net income for the fourth quarter 2011 ... 93 percent, compared to $116.5 million or $0.93 per share ...
Cached Medicine Technology:Report: CVS Caremark Contributes Billions to Rhode Island Economy 2Report: CVS Caremark Contributes Billions to Rhode Island Economy 3Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 2Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 3Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 4Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 5Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 6Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 7Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 8Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 9Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 10Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 11Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 12Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 13Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 14
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
(Date:4/17/2014)... in the April issue of Immunity , Kevin ... Medical Research, says it,s time to take a fresh ... sepsis, which kills millions worldwide every year, including ... released into the bloodstream to fight an injury or ... for maintaining good health without inflammation, wounds and ...
(Date:4/17/2014)... 17, 2014) Doctors who treat patients with ... (LAM) can face an agonizing treatment decision. , ... disease and help relieve shortness of breath. But ... sirolimus can cause potentially fatal complications following transplantation. ... Daniel Dilling, medical director of Loyola University Medical ...
(Date:4/17/2014)... April 17, 2014 By discovering a new mechanism ... a stroke, researchers at UC Irvine and the Salk ... may limit or prevent stroke-induced brain damage. , A ... cause of death and primary reason for disability in ... a stroke and lets blood-borne material into the brain, ...
(Date:4/17/2014)... potential to ward off depression among retirees, particularly among ... in The Journals of Gerontology, Series B: ... article " Internet Use and Depression Among Retired Older ... the authors report that Internet use reduced the probability ... study sample. , Late-life depression affects between 5 ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2
... Sayre Area School District in Bradford County today became ... H1N1 influenza vaccine to its student population, the Department ... reminded all parents that immunizations play a significant role ... disproportionately affecting school-aged children, with almost two-thirds of all ...
... into diseases and treatments, experts say , FRIDAY, Oct. ... detailed map of the human epigenome, gaining greater understanding ... past, we,ve been limited to viewing small snippets of ... Genomic Analysis Laboratory at the Salk Institute for Biological ...
... RATON, Fla., Oct. 16 Although stem cells sounds ... for quite some time. In today,s advanced medical ... orthopedic conditions including osteoarthritis of the hip knee and ... rotator cuff tears, and various back conditions including ...
... physicians will be using electronic prescribing and other health ... million federal grant secured by U.S. Senator Patrick Leahy. ... Technology Leaders, Inc. (VITL), will provide incentives to physicians ... In June, Vermont was cited by Surescripts as the ...
... DALLAS, Oct. 16 John Killian, Chairman of Parent ... the United States focused on finding a cure for Duchenne ... that the 5th Annual Sam,s Family Fun Day ... 10am to 2pm on Flagpole Hill at White Rock Lake. ...
... The Avon Foundation for Women is marking Breast ... celebrations, and tributes. Throughout October, the Foundation will call ... save lives, and raise millions of dollars for the ... the sale of fundraising products, Avon Walks for Breast ...
Cached Medicine News:Health News:Pennsylvania Department of Health Announces First School to Begin Administering H1N1 Vaccine to Students 2Health News:Scientists Provide First Map of Complete Human Epigenome 2Health News:Stem Cell and PRP Therapy for Orthopedic Conditions 2Health News:Stem Cell and PRP Therapy for Orthopedic Conditions 3Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 2Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 3Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 4Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 5Health News:Sam's Day Celebrates 5 Year Anniversary; Local Family Event Will Benefit Largest U.S. Non-Profit Fighting Duchenne Muscular Dystrophy 2Health News:Sam's Day Celebrates 5 Year Anniversary; Local Family Event Will Benefit Largest U.S. Non-Profit Fighting Duchenne Muscular Dystrophy 3Health News:Photos: Avon Foundation for Women Celebrates Breast Cancer Awareness Month 2Health News:Photos: Avon Foundation for Women Celebrates Breast Cancer Awareness Month 3
Anti Gliadin IgA Enzyme Immunosay for quantitative determination of Gliadin-IgG antibodies in serum....
... WorkCell System - A Single Platform ... hour, with true load-and-go productivity and ... Atlas and UF-100 for complete walkaway ... working together deliver utmost reliability. Ease ...
... high throughput primary or backup instrument, ... performance and reliability equal to or ... The advanced technology of the AUTION ... delivers reproducible and accurate results, limiting ...
... of the 3 major naturally occurring estrogens ... terms of estrogenic activity, estriol is much ... produced almost exclusively during pregnancy, and is ... human fetus. During pregnancy, the production of ...
Medicine Products: